S van Veen
Overview
Explore the profile of S van Veen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szachniewicz M, van den Eeden S, van Meijgaarden K, Franken K, van Veen S, Geluk A, et al.
Eur J Pharm Sci
. 2024 Dec;
205():106995.
PMID: 39710106
Tuberculosis (TB) remains a significant global health challenge, latently affecting around a quarter of the global population. The sole licensed TB vaccine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), shows variable efficacy,...
2.
Szachniewicz M, van den Eeden S, van Meijgaarden K, Franken K, van Veen S, Geluk A, et al.
Eur J Pharm Biopharm
. 2024 Aug;
203:114437.
PMID: 39122053
Tuberculosis (TB) has been and still is a global emergency for centuries. Prevention of disease through vaccination would have a major impact on disease prevalence, but the only available current...
3.
Eggenhuizen G, van Veen S, van Koetsveld N, Go A, Diderich K, Joosten M, et al.
Placenta
. 2024 Jun;
154:60-65.
PMID: 38901306
Objective: Non-invasive prenatal testing (NIPT) investigates placental DNA and may detect confined placental mosaicism (CPM). The aim of this study was to confirm CPM in the term placenta in cases...
4.
Heemskerk M, Korbee C, Esselink J, Dos Santos C, van Veen S, Gordijn I, et al.
Sci Rep
. 2021 Oct;
11(1):19634.
PMID: 34608194
The persistent increase of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) infections negatively impacts Tuberculosis treatment outcomes. Host-directed therapies (HDT) pose an complementing strategy, particularly since Mtb is highly successful in evading...
5.
van Veen S, Remmers S, Aarnoudse-Moens C, Oosterlaan J, van Kaam A, Van Wassenaer-Leemhuis A
Acta Paediatr
. 2018 Jul;
108(3):479-485.
PMID: 30047166
Aim: This study determined whether cognitive outcomes differed between very preterm (VPT) and extremely preterm (EPT) children who were monolingual or multilingual when they reached the corrected ages of two...
6.
van Veen S, Aarnoudse-Moens C, Oosterlaan J, van Sonderen L, de Haan T, van Kaam A, et al.
Early Hum Dev
. 2017 Dec;
117:39-43.
PMID: 29275071
Aim: To explore changes in motor and cognitive outcomes in very preterm (VP; gestational age<30weeks) born children between ages five and six years, and to determine whether changes in these...
7.
Srebniak M, Joosten M, Knapen M, Arends L, Polak M, van Veen S, et al.
Ultrasound Obstet Gynecol
. 2017 May;
51(4):445-452.
PMID: 28556491
Objective: To establish, based on a systematic literature review, the frequency of pathogenic submicroscopic chromosomal aberrations in fetuses that are not at increased risk for unbalanced structural chromosomal aberrations, with...
8.
Demirsoy S, Martin S, Motamedi S, van Veen S, Holemans T, Van den Haute C, et al.
Hum Mol Genet
. 2017 Mar;
26(9):1656-1669.
PMID: 28334751
ATP13A2 (also called PARK9), is a transmembrane endo-/lysosomal-associated P5 type transport ATPase. Loss-of-function mutations in ATP13A2 result in the Kufor-Rakeb Syndrome (KRS), a form of autosomal Parkinson's disease (PD). In...
9.
de Wit M, Srebniak M, Joosten M, Govaerts L, Kornelisse R, Papatsonis D, et al.
Ultrasound Obstet Gynecol
. 2016 Apr;
49(3):342-348.
PMID: 27102944
Objective: To assess phenotypic and genotypic characteristics of small-for-gestational-age (SGA) fetuses without structural anomalies at 18-24 weeks' gestation. Methods: This retrospective study included structurally normal singleton fetuses with an abdominal...
10.
van Dijk M, Kamper A, van Veen S, Souverijn J, Blauw G
Nephrol Dial Transplant
. 2001 Oct;
16(11):2152-7.
PMID: 11682660
Background: In animal models, HMG-CoA reductase inhibitors were able to improve renal function and endothelium-dependent vascular reactivity. In various experimental renal diseases, including autosomal dominant polycystic kidney disease (ADPKD), HMG-CoA...